Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects

Area of Science:

• Neuroscience
• Toxicology
• Radiology

Background:

• Ecstasy (3,4-methylenedioxymethamphetamine; MDMA) use can potentially lead to neurotoxic injury of the serotonin (5-HT) system.
• Direct evaluation of MDMA's neurotoxic effects in living humans was previously challenging.
• Advancements in in vivo neuroimaging have enabled new insights into MDMA's impact on the brain.

Purpose of the Study:

• To review and discuss neuroimaging studies (SPECT, PET, 1H-MRS) assessing the neurotoxic potential of MDMA.
• To examine the technical aspects, conceptual issues, and future directions in studying MDMA neurotoxicity.
• To evaluate the evidence for MDMA-induced changes in the serotonin system.

Main Methods:

• Review of studies utilizing Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and Proton Magnetic Resonance Spectroscopy (1H-MRS).
• Analysis of technical limitations including low cortical uptake and suboptimal reference regions in PET and SPECT studies.
• Assessment of study designs, primarily retrospective, and their implications for inferring causality.

Main Results:

• Suggestive evidence indicates heavy ecstasy users may exhibit reductions in serotonin transporter (SERT) densities, a marker of 5-HT neurotoxicity.
• These reductions appear to be dose-dependent and transient, with females potentially being more vulnerable than males.
• 1H-MRS demonstrated lower sensitivity in detecting MDMA's neurotoxic potential compared to PET and SPECT.

Conclusions:

• Neuroimaging provides evidence linking heavy MDMA use to reduced SERT densities in subcortical and potentially cortical regions.
• Further longitudinal studies are necessary to establish definitive causal links between MDMA exposure and SERT loss.
• The neurotoxic effects of MDMA on the serotonin system warrant continued investigation, especially regarding dose-dependency and gender differences.